retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Eli Lilly just announced striking results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% What GLP‑3 Really Is: Retatrutide

Liraglutide has shown significant weight loss compared with placebo with the majority of participants achieving more than 5% total body weight loss during the follow up period and 33% (vs 10%) achieving 10% total body weight loss or greater

10 Glycemic control A1c reductions in patients with T2DM, currently treated with MET or no therapy, resulting from treatment with GLP-1RA in randomized controlled trials (RCTs) are summarized in Table 1

That ended in 2023

Day 1 ADA/AACE Standards of Care Boot Camp Coach Beverly and Diana Isaacs, PharmD, BC-ADM, CDCES co-lead an exciting day that brings the ADA and AACE Standards to life